Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study

European Journal of Cancer

Volumn 37, Issue 3, 2001, Pages 364-368

  De Lena, M ^a   Lorusso, V ^a   Latorre, A ^a   Fanizza, G ^a   Gargano, G ^a   Caporusso, L ^a   Guida, M ^a   Catino, A ^a   Crucitta, E ^a   Sambiasi, D ^a   Mazzei, A ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Cisplatin; Lonidamine; Ovarian cancer; Paclitaxel; Phase II

Indexed keywords

CARBOPLATIN; CISPLATIN; LONIDAMINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDAZOLES; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 0035123284     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00400-7     Document Type: Article

References (20)

1. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma
2. New therapy for ovarian cancer
3. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
4. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial
5. Randomized phase III trial study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group Trial (GOG 158)
6. Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (GOG) Study Group Trial
7. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin
8. Lonidamine, a selective inhibitor of aerobic glycolisis of murine tumor cells
9. Lonidamine: An overview
10. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells
11. Use of lonidamine to potentiate the effect of cisplatin and carboplatin on platinum resistant human ovarian cancer cell
12. Recovery after response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results
13. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum
14. Correlation between HPLC-determined lonidamine serum levelsa and clinical response in patients with advanced ovarian cancer
15. Reporting results of cancer treatment
16. Non-parametric estimation from incomplete observations
17. Stimulation of apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumor xenograft
18. Lonidamine as a modulator of taxol activity in human ovarian cancer: Effects on cell cycle and induction of apoptosis
19. Lonidamine triggers apoptosis via a direct, Bcl-2 inhibited effect on the mitochondrial permeability transition pore
20. Bcl-2 inhibits mitochondrial methabolism and lonidamine induces apoptosis in adiamycin-resistant MCF 7 cells